June & July Newsmakers

ICYMI at Duke

How Small Moments of Praise Make a Big Difference: Simple displays of gratitude help to build culture and relationships (Duke Today)

Simple Test for Bug Can Help Prevent Stomach Cancer (Duke Health)
Features Meira Epplein, PhD, and Julius Wilder, MD, PhD

School of Medicine Establishes Onyekwere E. Akwari Endowed Professorship; Lisa McElroy Named Inaugural Recipient (Duke University School of Medicine)

Silicone Wristbands Track Firefighters’ Exposure to Harmful Chemicals (Nicholas School of the Environment)
Features Heather Stapleton, PhD

Dept. Welcomes Fan Lee, MD, Recipient of Prestigious ACOG Martin-Peterson Scholars Award (Duke Dept. OB/Gyn)

DCRI faculty member develops H. pylori Quality Measure to Reduce Rates of Failed Eradication (DCRI Blog)

Blue Devil of the Week: Rising Star Amanda Hargrove (Working at Duke)
Features Amanda Hargrove, PhD

'G'Owen Strong' for Brain Tumor Research (Giving to Duke Health)
Features Henry Friedman, MD

Media

SI Swim model Victoria Vesce recalls overcoming ‘nightmare’ brain tumor: ‘I had every symptom in the book’ (Fox News)
Features Duke University Hospital

This NC hospital is ranked nation’s second-most ‘socially responsible.’ Here’s why (Raleigh News & Observer *also carried by Yahoo News, AOL News)
Features Duke Regional Hospital

This is the best hospital in North Carolina (iHeart Radio)
Features Duke Regional Hospital

Oncología ginecológica; demasiado tratamiento hace más daño que bien (Palco Noticias (Es))
Features Brittany Davidson, MD

Leukemia Cure? Patient still cancer-free 11 years after innovative treatment (CBN News)
Features Ahmed Galal, MD, FRACP, MSc

Could an effective breast cancer therapy be bad for the heart? NIH awards $3.1M to find out (Cardiovascular Business)
Features Susan Dent, MD

Some doctors want to change how race is used in medicine (Science Friday)
Features Lisa McElroy, MD, MS

Trades, Institutions & Government Publications

New patient tumor cell models rapidly predict cancer therapy outcomes (The Scientist)
Features David Hsu, MD, PhD

Collaboration among oncologists and primary care physicians is key to closing the “black hole” in cancer survivorship care (Oncology Practice Management)
Features Kevin Oeffinger, MD

John Wayne Cancer Foundation to Fund Research to Limit Lymph Node Surgery For Women Suffering with Breast Cancer (John Wayne Cancer Foundation)
Features Maggie DiNome, MD

Dr. Ready on the Practice Implications of Nivolumab/Ipilimumab in NSCLC (Onc Live)
Features Neal Ready, MD

Severely ill children, treated with stem cells harvested at birth (Archynewsy)
Features Joanne Kurtzberg, PhD

Supportive Care Best Practices for Glioblastoma (Pharmacy Practice News)
Features Mallika Patel, PharmD, CPP

Reputation Most Important Factor in Choosing Breast Reconstruction Surgeon (Physician’s Weekly)
Features Amanda Sergesketter, MD

If Nuclear Disaster Strikes, U.S. Hematologists Stand Ready (MDEdge)
Features Nelson Chao, MD, MBA

Goldman Sachs Awards their One Million Black Women Impact Grant to "Touch, The Black Breast Cancer Alliance" (Touch)
Features Valarie Worthy, MSN, RN (Touch is a nonprofit co-founded by Worthy)

Lack of Mask Mandates Leaves Cancer Patients Feeling Unprotected (Cancer Therapy Advisor)
Features Arif Kamal, MD, MBA, MHS

Multi-Site Study Aims to Prevent Heart Disease in Young Breast Cancer Patients (Atrium Health)
Features Susan Dent, MD

Quizartinib Plus Chemo Significantly Improves OS Vs Chemo Alone in Newly Diagnosed FLT3-ITD+ AML (Onc Live)
Features Harry P. Erba, MD, PhD

EHA Congress 2022: Quizartinib, a new FLT3 Inhibitor Boosts Overall Survival (Health Tree Foundation)
Features Harry P. Erba, MD, PhD

Sotorasib Produces Encouraging Antitumor Activity in Heavily Pretreated KRAS G12C–Mutated Pancreatic Cancer (Onc Live)
Features John Strickler, MD

Biosimilars May Reduce Disparities in Febrile Neutropenia Treatment (Oncology Nursing News)
Features Jeffrey Crawford, MD

Loncastuximab shows favorable tolerability in relapsed/ refractory DLBCL (Targeted Oncology)
Features Matthew McKinney, MD

Overall Survival in the ARCHES Trial: Addition of Enzalutamide to ADT for Metastatic Hormone-Sensitive Prostate Cancer (The ASCO Post)
Features Andrew Armstrong, MD, MSc

Pandemic’s hardest hit breast-care segment: Screening mammography (Radiology Business)
Features Lars Grimm, MD, MHS, FSBI

ASCO 2022

#MyFirstASCO: Memories from 57 years of annual meetings (The Cancer Letter /Cancer History Project)
Features John Laszlo, MD (retired)

Results of Halabi Study Could Impact Time to Trials in mHS Prostate Cancer (DCI Blog)
Features Susan Halabi, PhD

Overall Survival in the ARCHES Trial: Addition of Enzalutamide to ADT for Metastatic Hormone-Sensitive Prostate Cancer (The ASCO Post)
Features Andrew Armstrong, MD, MSc

ASCO 2022: Olaparib Plus Abiraterone As First-Line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: Pharmacokinetics Data From the PROpel Trial (Uro Today)
Features Andrew J. Armstrong MD, MS

ESMO 2022

On Cusp of Merck Acquisition, Seagen Makes Waves in Colorectal Cancer AND Seagen, A Neuro Tech Starts July with a Clinical Bang (BioSpace)

Tucatinib Plus Trastuzumab Yields Long-Lasting Responses in Previously Treated HER2+ Metastatic CRC (Cancer Network)

Tukysa Plus Herceptin May Offer ‘Chemotherapy-Free’ Regimen for HER2-Positive Colon Cancer (Cure Today)

Seagen touts new Tukysa colorectal cancer data, setting up FDA filing and a potential $500M opportunity (Fierce Pharma)

Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC AND Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC AND Dr. Strickler on the Efficacy of Tucatinib/ Trastuzumab in HER2+ Colorectal Cancer (OncLive)

Tucatinib Plus Trastuzumab Yields Clinically Meaningful Antitumor Activity in HER2-Positive Metastatic Colorectal Cancer (Oncology Learning Network)

Tucatinib/Trastuzumab Combo Elicits Tumor Response in HER2+ mCRC (Oncology Nursing News)

Pivotal Trial Demonstrates Antitumor Activity With Tucatinib, Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer (Pharmacy Times)

Tucatinib Plus Trastuzumab Provides Durable Responses in Patients With HER2-Positive mCRC (Targeted Oncology)

Seagen releases data from Tukysa pivotal trial in HER2+ mCRC (The Pharma Letter)

Papers

Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice Annals of Surgery July 7, 2022 Rhodin, Kristen E. MD; Gaughan, Elizabeth M. MD; Raman, Vignesh MD, MHS; Salama, April K. MD; Hanks, Brent A. MD, PhD; Shah, Riddhishkumar MD; Tyler, Douglas S. MD; Slingluff, Craig L. Jr MD; Beasley, Georgia M. MD MHS

G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment Cell Reports June 28, 2022 Shree Bose; Qiang Huang; Yunhan Ma; Lihua Wang; Grecia O. Rivera; Yunxin Ouyang; Regina Whitaker; Rebecca A. Gibson; Christopher D. Kontos; Andrew Berchuck; Rebecca A. Previs; Xiling Shen

Iatrogenic Cushing's syndrome presenting with adrenal insufficiency in 2 patients receiving dexamethasone for metastatic colorectal cancer through an intrahepatic arterial infusion pump Current Problems in Cancer: Case Reports via Science Direct June 28, 2022 Michelle N. Ferreira; Afreen I. Shariff

Association of area-level socioeconomic status and non–small cell lung cancer stage by race/ethnicity and health care–level factors: Analysis of the National Cancer Database  Cancer June 20, 2022 Tomi F. Akinyemiju PhD, MS, Ashwini R. Joshi MPH, MPH, Jessica Y. Islam PhD, Chioma H. Omeogu BA, Anjali Gupta BS

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia Nature June 6, 2022 Kevin H. Lin, Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, Gaetano Sodaro, Paul-Arthur Meslin, Christopher F. Bassil, Nina Fenouille, Jacob Hoj, Rachel Washart, Hazel X. Ang, Christian Cerda-Smith, Paul Chaintreuil, Arnaud Jacquel, Patrick Auberger, Antoine Forget, Raphael Itzykson, Min Lu, Jiaxing Lin, Mariaelena Pierobon, Zhecheng Sheng, Xinghai Li, Ashutosh Chilkoti, Kouros Owzar, David A. Rizzieri, Timothy S. Pardee, Lina Benajiba, Emanuel Petricoin, Alexandre Puissant & Kris C. Wood

Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence–Guided System May 11, 2022 JAMA Surgery E. Shelley Hwang, MD, MPH; Peter Beitsch, MD; Peter Blumencranz, MD; David Carr, MD; Anees Chagpar, MD, MBA, MPH; Lynne Clark, MD; Nayana Dekhne, MD; Daleela Dodge, MD; Donna L. Dyess, MD; Linsey Gold, DO; Stephen Grobmyer, MD; Kelly Hunt, MD; Stephen Karp, MD; Beth-Ann Lesnikoski, MD; Irene Wapnir, MD; Barbara L. Smith, MD, PhD; for the INSITE study team

Characterizing Firefighter's Exposure to Over 130 SVOCs Using Silicone Wristbands: A Pilot Study Comparing On-Duty and Off-Duty Exposures Science of the Total Environment April 26, 2022 Jessica L. Levasseur, Kate Hoffman, Nicholas J. Herkert, Ellen Cooper, Duncan Hay and Heather M. Stapleton

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents Clinical Genitourinary Cancer April 23, 2022 Lisa P. Spees; Michaela A. Dinan; Bradford E. Jackson; Christopher D. Baggett; Lauren E. Wilson; Melissa A. Greiner; Deborah R. Kaye; Tian Zhang; Daniel J. George; Charles D. Scales; Jessica E. Pritchard; Michael Leapman; Cary P. Gross; Stephanie B. Wheeler.

Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease Annals of Surgical Oncology April 9, 2022 Miquel Ensenyat-Mendez MSc, Dennis Rünger PhD, Javier I. J. Orozco MD, Julie Le MD, Jennifer L. Baker MD, Joanne Weidhaas MD, PhD, Diego M. Marzese PhD & Maggie L. DiNome MD

(Editorial) Opportunities to Advance the Delivery of High-Quality, Goal-Concordant End-of-Life Care in Ovarian Cancer JCO Oncology Practice March 1, 2022 Brittany Davidson, MD; Laura Havrilesky, MD; and Carolyn Lefkowitz, MD